Navigation Links
Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal(TM) for the Treatment of Fabry Disease
Date:6/22/2009

t costs on a 50/50 basis, and in return Shire received rights to commercialize these products outside of the U.S. while Amicus retains all rights to commercialize these products in the U.S. In addition, Amicus leads development operations through the end of Phase 2 clinical trials. The companies then share responsibility for Phase 3 clinical trial development leveraging Shire's significant ex-U.S. regulatory and clinical experience as well as its commercial infrastructure.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs.

Amicus has a strategic collaboration with Shire Human Genetic Therapies, Inc., a wholly-owned subsidiary of Shire Limited, to develop and commercialize Amicus' three lead pharmacological chaperone compounds for lysosomal storage disorders. Under the agreement, Shire received commercial rights outside of the United States. Amicus retains all U.S. rights.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "should" and "could," and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances,
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
2. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
3. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
4. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
5. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
6. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
7. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
8. Amicus Therapeutics Announces Second Quarter 2008 Financial Results
9. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
10. Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
11. Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... & Forecast – Worldwide Analysis ... Pump Market Analysis ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Drug Delivery Systems -- Focus on End ... STUDY OBJECTIVES A drug ...
(Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly ... and painless for patients to self-inject prescription drugs in the ... including cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... grow to $220B by 2018, according to analysts.   Many of ...
Breaking Medicine Technology:Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2
... Evidence Report Compares Effectiveness of CT Colonography to ... The value of CT colonography, also called virtual ... coverage of these procedures as a diagnostic method ... findings from meta-analyses performed by ECRI Institute suggest ...
... March 12 The following is being issued by Coast ... March 10, 2009, Coast IRB informed the public that it ... submitted to that Independent review board for evaluation. Coast ... commenced as part of a congressional "sting" operation. Apparently ...
Cached Medicine Technology:Virtual Colonoscopies Show Value for Some Patients, But Polyps Will Be Missed 2Virtual Colonoscopies Show Value for Some Patients, But Polyps Will Be Missed 3Congressional 'Sting' Operation Uncovered By Coast IRB 2
(Date:4/24/2014)... long thought to be boring and irrelevant, could offer ... disease. , Researcher Dr Milena Furtado, and her team ... University, found the heart cell fibroblast is a close ... healthy beating heart. , In research published today in ... cardiac fibroblasts are unique cells due to their genetic ...
(Date:4/24/2014)... one out of three survivors of critical illness, ... The Lancet Respiratory Medicine , and the majority ... mentally. , It is one of the largest ... outcomes of critical care survivors, according to lead ... and it highlights a significant public health issue, ...
(Date:4/24/2014)... NH, 4/24/14) Dartmouth has been awarded one of ... serve as a Lead Academic Participating Site in its ... Award recipients are a select groups of investigators charged ... fewer cooperative groups., The NCTN grant system reflects recommendations ... It streamlines operations to achieve four goals:, ...
(Date:4/24/2014)... In 2009 the influenza pH1N1 virus caused the first ... Finland in May 2009 and killed more than 50 ... infects Finns mainly during flu epidemics (winter/spring seasons). ... to serious complicated illnesses. World Health Organization has recommended ... illness. The disadvantage of this drug is that it ...
(Date:4/23/2014)... was safe and effective in treating patients with ... , according to a new pilot study published ... online. Known as fecal microbiota transplantation, the treatment ... or a nasogastric tube. The findings suggest approaches ... available to patients. , A growing concern, ...
Breaking Medicine News(10 mins):Health News:Boring cells could hold the key to heart disease 2Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 2Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 3Health News:Dartmouth awarded lead role in NCI clinical trials network 2Health News:Dartmouth awarded lead role in NCI clinical trials network 3Health News:Pilot study suggests ways to widen access to fecal transplants for C. diff infections 2
... first time that coffee beans contain proteins that can kill ... food crops against destructive pests. Their study, which suggests a ... in the world, appears in ACS, Journal of Agricultural ... and some other plant seeds contain proteins, called globulins, which ...
... for Passover and year-round: With observant Jews numbering barely one ... are 40-50 percent of food items on supermarket shelves kosher? ... popularity of kosher foods appear in an article in ... C&EN Senior Editor Bethany Halford notes that the number ...
... it takes to get things done, research shows , WEDNESDAY, ... how long it will take to do something, don,t ask ... toward optimism and are less likely to make an accurate ... predictions much more than others, and their error rates can ...
... safety of increasingly popular imaging procedures such as virtual ... that popular medical imaging technologies are exposing Americans to ... week as the U.S. Food and Drug Administration concludes ... on how to increase the safety of these procedures. ...
... ... innovative, value-focused approach to streamline litigation and compliance management. Taking a proactive stance ... review team - cuts project costs substantially. , ... (PRWEB) March 31, 2010 -- HLP Integration (“HLP”) and Pat ...
... ... for Swimsuit Season. , ... (PRWEB) March 31, 2010 -- The Knowland Group , a leading provider ... 2010 Knowland Fitness Challenge. Designed to help employees improve their overall health and get ...
Cached Medicine News:Health News:Powerful People Often Too Optimistic About Task Time 2Health News:FDA Hears Views on Risks of High Tech Scanners 2Health News:FDA Hears Views on Risks of High Tech Scanners 3Health News:FDA Hears Views on Risks of High Tech Scanners 4Health News:HLP Integration and Pat Taylor and Associates, Inc. Announce a Project Alliance. 2Health News:Knowland Group Kicks Off Employee Fitness Challenge with Award-Winning Body Builder and Personal Trainer Dave Kergaard 2Health News:Knowland Group Kicks Off Employee Fitness Challenge with Award-Winning Body Builder and Personal Trainer Dave Kergaard 3
... the storage of blood plasma in full ... attention to operating temperatures and performance means ... Standard freezer you will minimise bag cracking ... temperature an additional benefit is reduced thawing ...
Helmer offers Plasma Storage Freezer lines, the i.Series ipf 125-8. It is Designed to complement Blood Bank Refrigerators, it freezers offer outstanding features, including programmable defrost tim...
... PillCam SB Capsule Endoscope is a ... the gastrointestinal tract. Natural peristalsis moves ... painlessly throughout the gastrointestinal tract, transmitting ... The procedure is ambulatory, allowing patients ...
... 1400 Series Biosafety Cabinets ... revolutionize working in a ... most comfortable, quiet, and ... cabinet on the market, ...
Medicine Products: